Biological platforms
Biology is becoming an engineering discipline. We invest in platforms that make biological systems programmable, measurable, and manufacturable — with clear paths from discovery to clinical and commercial deployment.
The convergence of computation, automation, and biological understanding is creating a new class of platform companies. These are not single-product bets — they are systems that accelerate discovery, improve clinical translation, and reduce the cost of bringing biological innovations to market. We look for defensible platform architectures with multiple shots on goal.
Therapeutic platforms
Novel modalities including RNA therapies, gene editing, engineered biologics, and precision oncology approaches with platform-scale potential.
Diagnostic intelligence
High-throughput molecular diagnostics, liquid biopsy, and AI-augmented pathology systems for earlier and more accurate disease detection.
Synthetic biology
Engineered biological systems for industrial production, agriculture, and materials — biology as a manufacturing platform.
Clinical infrastructure
Tools, data systems, and automation that reduce the cost and timeline of clinical development and regulatory approval.
- Development timelines and costs in life sciences remain high — platforms that improve predictability can reshape economics.
- The Nordics offer strong science, longitudinal data, and pragmatic regulatory dialogue relative to many peers.
- Better diagnostics and biomarkers improve outcomes and make development and reimbursement decisions clearer.
- Industrial biomanufacturing is increasingly strategic for resilience and supply security in Europe.
Industrial infrastructure
→Hardware, materials, and advanced manufacturing with durable moats in physical industries.